Works by Hong Jae Chon

Results: 55
    1
    2
    3
    4
    5
    6

    Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population.

    Published in:
    Oncologist, 2025, v. 30, n. 3, p. 1, doi. 10.1093/oncolo/oyae256
    By:
    • Prinzi, Federica Lo;
    • Salani, Francesca;
    • Rimini, Margherita;
    • Rizzato, Mario Domenico;
    • Antonuzzo, Lorenzo;
    • Camera, Silvia;
    • Satake, Tomoyuki;
    • Vandeputte, Hanne;
    • Vivaldi, Caterina;
    • Pressiani, Tiziana;
    • Lucchetti, Jessica;
    • Kim, Jin Won;
    • Abidoye, Oluseyi;
    • Rapposelli, Ilario Giovanni;
    • Tamberi, Stefano;
    • Finkelmeier, Fabian;
    • Giordano, Guido;
    • Pircher, Chiara;
    • Chon, Hong Jae;
    • Braconi, Chiara
    Publication type:
    Article
    7
    8

    Disease Etiology Impact on Outcomes of Hepatocellular Carcinoma Patients Treated with Atezolizumab plus Bevacizumab: A Real-World, Multicenter Study.

    Published in:
    Liver Cancer (2235-1795), 2024, v. 13, n. 5, p. 522, doi. 10.1159/000537915
    By:
    • Rossari, Federico;
    • Tada, Toshifumi;
    • Suda, Goki;
    • Shimose, Shigeo;
    • Kudo, Masatoshi;
    • Yoo, Changhoon;
    • Cheon, Jaekyung;
    • Finkelmeier, Fabian;
    • Lim, Ho Yeong;
    • Presa, José;
    • Masi, Gianluca;
    • Bergamo, Francesca;
    • Amadeo, Elisabeth;
    • Vitiello, Francesco;
    • Kumada, Takashi;
    • Sakamoto, Naoya;
    • Iwamoto, Hideki;
    • Aoki, Tomoko;
    • Chon, Hong Jae;
    • Himmelsbach, Vera
    Publication type:
    Article
    9
    10
    11
    12
    13
    14
    15

    Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis.

    Published in:
    Therapeutic Advances in Medical Oncology, 2022, p. 1, doi. 10.1177/17588359221097934
    By:
    • Bang, Yeong Hak;
    • Lee, Choong-kun;
    • Yoo, Changhoon;
    • Chon, Hong Jae;
    • Hong, Moonki;
    • Kang, Beodeul;
    • Kim, Hyung-Don;
    • Park, Sook Ryun;
    • Choi, Won-Mook;
    • Choi, Jonggi;
    • Lee, Danbi;
    • Shim, Ju Hyun;
    • Kim, Kang Mo;
    • Lim, Young-Suk;
    • Lee, Han Chu;
    • Ryu, Min-Hee;
    • Ryoo, Baek-Yeol
    Publication type:
    Article
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26

    Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?

    Published in:
    Targeted Oncology, 2023, v. 18, n. 2, p. 221, doi. 10.1007/s11523-023-00953-x
    By:
    • Rimini, Margherita;
    • Persano, Mara;
    • Tada, Toshifumi;
    • Suda, Goki;
    • Shimose, Shigeo;
    • Kudo, Masatoshi;
    • Cheon, Jaekyung;
    • Finkelmeier, Fabian;
    • Lim, Ho Yeong;
    • Presa, José;
    • Masi, Gianluca;
    • Yoo, Changhoon;
    • Lonardi, Sara;
    • Piscaglia, Fabio;
    • Kumada, Takashi;
    • Sakamoto, Naoya;
    • Iwamoto, Hideki;
    • Aoki, Tomoko;
    • Chon, Hong Jae;
    • Himmelsbach, Vera
    Publication type:
    Article
    27
    28
    29
    30
    31
    32
    33

    Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group.

    Published in:
    Therapeutic Advances in Medical Oncology, 2019, v. 11, p. 1, doi. 10.1177/1758835919871126
    By:
    • Yoo, Changhoon;
    • Im, Hyeon-Su;
    • Kim, Kyu-pyo;
    • Oh, Do-Youn;
    • Lee, Kyung-Hun;
    • Chon, Hong Jae;
    • Kim, Joo Hoon;
    • Kang, Myoungjoo;
    • Kim, Ilhwan;
    • Lee, Guk Jin;
    • Oh, Sung Yong;
    • Choi, Younak;
    • Choi, Hye Jin;
    • Kim, Seung Tae;
    • Park, Joon Oh;
    • Ryoo, Baek-Yeol
    Publication type:
    Article
    34

    Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group.

    Published in:
    Therapeutic Advances in Medical Oncology, 2019, v. 11, p. N.PAG, doi. 10.1177/1758835919871126
    By:
    • Yoo, Changhoon;
    • Im, Hyeon-Su;
    • Kim, Kyu-pyo;
    • Oh, Do-Youn;
    • Lee, Kyung-Hun;
    • Chon, Hong Jae;
    • Kim, Joo Hoon;
    • Kang, Myoungjoo;
    • Kim, Ilhwan;
    • Lee, Guk Jin;
    • Oh, Sung Yong;
    • Choi, Younak;
    • Choi, Hye Jin;
    • Kim, Seung Tae;
    • Park, Joon Oh;
    • Ryoo, Baek-Yeol
    Publication type:
    Article
    35

    Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients.

    Published in:
    Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 10, p. 7565, doi. 10.1007/s00432-023-04678-2
    By:
    • Rimini, Margherita;
    • Persano, Mara;
    • Tada, Toshifumi;
    • Suda, Goki;
    • Shimose, Shigeo;
    • Kudo, Masatoshi;
    • Cheon, Jaekyung;
    • Finkelmeier, Fabian;
    • Lim, Ho Yeong;
    • Presa, José;
    • Salani, Francesca;
    • Lonardi, Sara;
    • Piscaglia, Fabio;
    • Kumada, Takashi;
    • Sakamoto, Naoya;
    • Iwamoto, Hideki;
    • Aoki, Tomoko;
    • Chon, Hong Jae;
    • Himmelsbach, Vera;
    • Schirripa, Marta
    Publication type:
    Article
    36

    Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study.

    Published in:
    Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 9, p. 5591, doi. 10.1007/s00432-022-04512-1
    By:
    • Persano, Mara;
    • Rimini, Margherita;
    • Tada, Toshifumi;
    • Suda, Goki;
    • Shimose, Shigeo;
    • Kudo, Masatoshi;
    • Cheon, Jaekyung;
    • Finkelmeier, Fabian;
    • Lim, Ho Yeong;
    • Rimassa, Lorenza;
    • Presa, José;
    • Masi, Gianluca;
    • Yoo, Changhoon;
    • Lonardi, Sara;
    • Tovoli, Francesco;
    • Kumada, Takashi;
    • Sakamoto, Naoya;
    • Iwamoto, Hideki;
    • Aoki, Tomoko;
    • Chon, Hong Jae
    Publication type:
    Article
    37
    38
    39
    40
    41

    Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE‐063): A randomized, open‐label, phase 3 trial in Asian patients.

    Published in:
    Cancer (0008543X), 2022, v. 128, n. 5, p. 995, doi. 10.1002/cncr.34019
    By:
    • Chung, Hyun Cheol;
    • Kang, Yoon‐Koo;
    • Chen, Zhendong;
    • Bai, Yuxian;
    • Wan Ishak, Wan Zamaniah;
    • Shim, Byoung Yong;
    • Park, Young Lee;
    • Koo, Dong‐Hoe;
    • Lu, Jianwei;
    • Xu, Jianming;
    • Chon, Hong Jae;
    • Bai, Li‐Yuan;
    • Zeng, Shan;
    • Yuan, Ying;
    • Chen, Yen‐Yang;
    • Gu, Kangsheng;
    • Zhong, Wen Yan;
    • Kuang, Shu;
    • Shih, Chie‐Schin;
    • Qin, Shu‐Kui
    Publication type:
    Article
    42
    43
    44
    45
    46
    47
    48
    49
    50